Phase 2 Study of VAL-083 Treatment for MGMT Unmethylated Bevacizumab-Naive Glioblastoma in the Adjuvant or Recurrent Setting
MD Anderson Study Status
The purpose of this phase 2, two arm, biomarker-driven study is to determine if treatment of O-6-methylguanine-DNA methyltransferase (MGMT) unmethylated glioblastoma with VAL-083 improves overall survival (OS), compared to historical control, in the adjuvant or recurrent setting.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Glioma, Glioblastoma, Glioblastoma Multiforme, GBM, Brain Cancer
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.